Navigation Links
Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Date:9/5/2007

a's lead anticancer drug, is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of cancer treatment resistance. By knocking down Bcl-2, Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma. Genasense in melanoma has Orphan Drug designations in Australia and the U.S., along with Fast Track designation in the U.S.

In its initial Phase 3 trial, Genta performed the largest randomized controlled trial that has ever been conducted in patients with advanced melanoma. In that trial, 771 patients were randomly assigned to receive chemotherapy with DTIC alone or in combination with Genasense. A scientific article that describes efficacy and safety results from this study can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1.

In that trial, patients were prospectively stratified according to levels of a blood enzyme known as LDH. Further analysis of this study showed that maximum benefit accrued to patients whose LDH biomarker did not exceed 80% of the upper limit of normal. Efficacy results in this group of 274 patients, which are the focus of the confirmatory AGENDA trial, are displayed in the table below. (The hazard ratios indicate that the addition of Genasense to DTIC was associated with a 42% reduction in the risk of disease progression and a 36% reduction in risk of death.)

Endpoint Genasense/DTIC DTIC Hazard P

Ratio

Overall response 20.8 % 7.2 % 0.002

Durable response 10.7 % 2.4 % 0.007

Progression-free survival,

median 3.6 mos. 1.6 mos. 0.58 <0.0001

Overall survival, median 12.3 mos. 9.9 mos. 0.64 0.0009

A
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
2. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
3. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
4. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
5. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
8. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Diplomat, the ... as one of two winners in the 2014 ... Pharmacy Solutions, LLC. The results of the competition ... Specialty Pharmacy News. Diplomat was ... University Education & Training program. Through Diplomat University, ...
(Date:8/22/2014)... 2014 Research and Markets  has announced ... Opportunities, Tools & Technologies" report to their offering. ... research products or you wish to expand your product ... market is. The authors know you want to make ... scientists, to generate improved revenues and take market share ...
(Date:8/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The intravenous ...
Breaking Medicine Technology:Diplomat honored as a Top Innovator by Specialty Pharmacy News 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Global and Chinese Intravenous Catheter Industry Report 2014 2
... Cell Therapeutics, Inc. (the "Company") (NASDAQ and MTA: CTIC) ... "Board") approved a reverse stock split following the Company,s ... non-compliance from the staff of The NASDAQ Stock Market ... not regained compliance with NASDAQ Listing Rule 5550(a)(2) because ...
... Talnadge, a power wheelchair provided through Medicare is the ... to visit with friends and engage in the community, ... Those starkly different living environments are the only ... from muscular dystrophy and spina bifida.  These medical conditions ...
Cached Medicine Technology:Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing 2Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing 3Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing 4Power Wheelchairs Keep Medicare Beneficiaries Out of Nursing Homes, While Reducing Government Costs and Providing More Freedom and Independence 2Power Wheelchairs Keep Medicare Beneficiaries Out of Nursing Homes, While Reducing Government Costs and Providing More Freedom and Independence 3Power Wheelchairs Keep Medicare Beneficiaries Out of Nursing Homes, While Reducing Government Costs and Providing More Freedom and Independence 4
(Date:8/23/2014)... Board of Directors voted on Monday, August 18th to approve ... for commercial and industrial properties. This was accomplished with ... in Carmel, California. , This is a historical moment, ... the State of California has approved this technology for use ... can now be used as a sole source of water ...
(Date:8/23/2014)... 23, 2014 Dealing with a drug or ... when the addict is a child. Adolescent addiction has been ... long time, but a new helpline is now providing a ... parents to find a real addiction recovery center. , The ... positive impact in the community. By calling (404) 975-2762, parents ...
(Date:8/23/2014)... vacation is almost over and before we know it schools ... school supplies and a new wardrobe might take precedence over ... also spend some time brushing up on bed bug prevention ... heavily populated places,” said Randy Rupert, Bed Bug Team Lead ... for bed bugs to take up residence.” , An already ...
(Date:8/22/2014)... On Friday, Aug. 22, Liberty University ... Sciences , hosting a ceremony in its courtyard attended ... and public welfare. , The 162-member inaugural class of ... (LUCOM) joined Liberty staff, faculty, and community leaders in ... new medical school. Classes began on Monday, Aug. 4. ...
(Date:8/22/2014)... Top 10 Best SEO Hosting (Top10BestSEOHosting.com) has ... highly recommended FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ) and BlueHost ... 10 Best SEO Hosting states, “It is hard ... Actually, these companies have outperformed their competitors on ... People can get the best web hosting at ...
Breaking Medicine News(10 mins):Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2Health News:Expert Advice for a Bed Bug-Free School Year 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4Health News:FatCow Reviews Released by Top10BestSEOHosting.com 2
... undertaken by a group of Spanish scientists, amongst which ... of Navarra and the Centre for Applied Medical Research// ... new line of treatment for patients with acute lymphoblastic ... been published in the official journal, Blood, of the ...
... is an independent risk factor for HIV infection, according ... of Sexually Transmitted Infections. The researchers conducted// a meta-analysis ... studies looking at the link between smoking and progression ... ,There is a growing recognition that smoking can ...
... are most likely to gain weight, a new study says//. ... aged nine and 10 and followed them for at least a ... cholesterol every year through age 18, then had the teens report ... the girls were white and half were black. ,The ...
... According to a recent study led by John-Dylan Haynes, ... cortex as subjects// concentrated on their choice of two ... activity patterns that correspond to the subjects' different plans. ... group led by John-Dylan Haynes of the Max Planck ...
... now for Trevis Smith, once- upon- a -time hero of Regina//. ... aggravated sexual assault last Thursday. , The 31-year-old football ... trial, which has been going on for some time. ... term of minimum two years and maximum, life. ,Two ...
... checkup in pregnant women to get underway soon//. ... mandatory in pregnant women, even if no symptoms of the ... slightly under active or a hyperactive thyroid gland during pregnancy ... lower IQ's. ,2-5 percent of women in general ...
Cached Medicine News:Health News:A New Treatment Discovered For Acute Lymphoblastic Leukemia 2Health News:Smoking Increases Risk of HIV Acquisition 2Health News:Adolescent Girls More Likely to Gain Weight: Study 2Health News:Reading Hidden Intentions in Brain 2Health News:Pregnant? Check Your Thyroid Secretion! 2
... Provides a more occlusive wrap than ... where wound transudate must be contained. Predictable ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ... synthetic absorbable copolymer of glycolide and lactide, ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... mesh onlays are pre-cut and pre-shaped to ... are more frequently done. These pre-shaped onlays ... ProLite Ultra and are designed for use ... in both small and large sizes, they ...
... such as laparoscopic inguinal hernia repair ... a surgical biomaterial that enables rapid ... provides the answer to the most ... Made from strong, soft, inert and ...
Medicine Products: